Spurred by the identification of androgen receptors (AR) as potential treatment targets in prostate cancer, clinicians and researchers have proposed the use of AR expression (as assessed by immunohistochemistry) as a criterion to stratify TNBC patients for AR-targeted therapies. Here, AR is linked to prostate carcinoma.